Early PRGN-3005 Data May Reignite CAR T-cell Research for Ovarian Cancer


PRGN-3005 autologous UltraCAR-T cells appear well-tolerated and decreases tumor burden in a population of patients with advanced platinum-resistant ovarian cancer.

Although previous studies assessing CAR T-cell therapies in the ovarian cancer space have been negative, the modality may still have potential via novel products such as PRGN-3005 autologous UltraCAR-T cells, according to Mary L. Disis, MD.

In an interview with CancerNetwork® during the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Disis, a professor of the Clinical Research Division at Fred Hutch Cancer Center, discusses her hope that phase 1 findings (NCT03907527) assessing PRGN-3005 in advanced stage, platinum-resistant ovarian cancer may reignite interest in CAR T-cell therapy research in this space.


CAR T-cell products in the ovarian cancer space have been tested and haven't seemed to be that effective. They were done with first generation technologies, and one of the major problems was that they really didn't persist in the body, so they really didn't have much of an anti-tumor effect. With strategies such as this—engineering agents to help those CAR T-cell products persist—we'll start seeing clinical efficacy with these products in ovarian cancer.

People are looking at some of these newer technologies and bringing them to different cancers. Ovarian cancer has been a little bit of a problem for 2 reasons: Number one, there were some very early studies that turned out to be negative, and that usually drives people away from using that as their first studies. And then the second thing is that people are very curious about what the route of administration should be: intraperitoneal or intravenous. I'm hoping that once this phase 1 study is published, showing some level of efficacy and also addressing those issues of dosing, we'll bring more people working on CAR T cells back to ovarian cancer. This is because in cisplatin-refractory ovarian cancer, we certainly do need many more treatment options.


Liao JB, Stanton S, Chakaith M, et al. Phase 1/1b study of PRGN-3005 autologous UltraCAR-T cells manufactured overnight for infusion next day to advanced stage platinum resistant ovarian cancer patients. J Clin Oncol. 2023; 41(suppl 16):5590. doi:10.1200/JCO.2023.41.16_suppl.5590

Related Videos
The August CancerNetwork Snap Recap takes a look back at key FDA news updates, as well as expert perspectives on the chemotherapy shortage.
Common adverse effects following treatment with lenvatinib plus pembrolizumab in the phase 3 CLEAR study include diarrhea, hypertension, and fatigue, according to Thomas E. Hutson, DO, PharmD, FACP.
Implementing tax benefits for manufacturers who produce chemotherapy drugs may be one solution to increase drug production in the United States, according to Lucio N. Gordan, MD.
Lucio N. Gordan, MD, describes how his practice deals with increasing costs of limited chemotherapy agents to ensure that patients with cancer continue to receive treatment.
Lucio N. Gordan, MD, also discusses how increasing domestic manufacturing of chemotherapy may help in alleviating the ongoing shortages of carboplatin and cisplatin in the United States.
Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, believes that national legislation can help to resolve the United States’ current dearth of cisplatin, as well as prevent future problems.
Using an AUC of 5 instead of an AUC of 6 can help to conserve cisplatin among patients with cancer, Kirollos Hanna, PharmD, BCPS, BCOP, FACCC says.
Future developments in the sarcoma space may also involve research on circulating tumor DNA and metabolic therapies, according to Brian Van Tine, MD, PhD.
Guidelines from the Society of Gynecologic Oncology may help with managing the ongoing chemotherapy shortage in the treatment of patients with gynecologic cancers, according to Brian Slomovitz, MD, MS, FACOG.
Current research in the sarcoma space includes the development of treatment options such as T-cell therapies, and combinations such as TKIs/immunotherapy, according to Brian Van Tine, MD, PhD.